Thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Large and unusually large von Willebrand factor (vWf) multimers may be responsible for systemic platelet aggregation in thrombotic thrombocytopenic purpura (TTP). This possibility is supported by studies that show deficient vWf-cleaving metalloproteinase and increased platelet-vWf binding during TTP episodes. In acute idiopathic TTP, decreased vWf metalloproteinase is the result of autoantibodies against the enzyme. In familial and acquired hemolytic-uremic syndrome, vWf-cleaving metalloproteinase activity is normal. A deficiency or defect in factor H, which normally dampens the activation of C3 via the alternative complement pathway, has been seen in some patients with familial hemolytic-uremic syndrome. Ticlopidine therapy is an important risk factor for TTP.
Baker
K R
KR
Baylor College of Medicine, Houston, Texas, USA.
Moake
J L
JL
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D003937:Diagnosis, Differential; D004921:Erythropoietin / Q000172:deficiency; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D016019:Survival Analysis; D013988:Ticlopidine / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D004921:Erythropoietin; D013988:Ticlopidine